(RAPP) Rapport Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.683m USD | Total Return: 239.2% in 12m
Avg Turnover: 9.49M
Warnings
Share dilution 144.9% YoY
High Debt while negative Cash Flow
Altman Z'' -7.81 < 1.0 - financial distress zone
Volatile
Tailwinds
Leader
Rapport Therapeutics, Inc. (RAPP) is a clinical-stage biopharmaceutical firm specializing in small molecule treatments for central nervous system (CNS) disorders. The company’s primary focus is its lead candidate, RAP-219, which targets specific AMPA receptors to treat conditions such as focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additionally, the firm is advancing programs targeting nicotinic acetylcholine receptors for the treatment of chronic pain, migraines, and hearing disorders.
Operating within the biotechnology sector, Rapport utilizes a precision neuroscience platform designed to improve drug selectivity by targeting receptor-associated proteins. This business model aims to reduce the off-target side effects commonly associated with traditional CNS medications. Investors may find ValueRay useful for conducting deeper due diligence on this sector.
Headquartered in Boston, Massachusetts, the company was established in 2022 following a name change from Precision Neuroscience NewCo, Inc. It currently operates as a pre-revenue entity, typical for clinical-stage firms focused on the multi-year regulatory approval process required by the FDA.
- RAP-219 clinical trial data readouts for focal epilepsy drive valuation
- Regulatory approval timeline for TARPy8-containing AMPAR inhibitors impacts stock
- Expansion of pipeline into neuropathic pain and bipolar disorder markets
- R&D cash burn rate influences long-term capital requirements and dilution
- Competitive landscape for CNS small molecule therapeutics affects market share
| Net Income: -107.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA 6.68 > 1.0 |
| NWC/Revenue: 2.33k% < 20% (prev 39.1k%; Δ -36.8k% < -1%) |
| CFO/TA -0.16 > 3% & CFO -80.3m > Net Income -107.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.2m) vs 12m ago 144.9% < -2% |
| Gross Margin: 94.92% > 18% (prev -0.29%; Δ 9.52k% > 0.5%) |
| Asset Turnover: 5.00% > 50% (prev 0.24%; Δ 4.76% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 484.7m - Total Current Liabilities 17.9m) / Total Assets 497.6m |
| B: -0.51 (Retained Earnings -255.1m / Total Assets 497.6m) |
| C: -0.30 (EBIT TTM -119.1m / Avg Total Assets 399.8m) |
| D: -9.80 (Book Value of Equity -255.5m / Total Liabilities 26.1m) |
| Altman-Z'' = -7.81 = D |
As of May 24, 2026, the stock is trading at USD 36.70 with a total of 317,177 shares traded.
Over the past week, the price has changed by +1.75%,
over one month by +2.56%,
over three months by +25.23% and
over the past year by +239.21%.
Rapport Therapeutics has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy RAPP.
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 55.9 | 52.3% |
P/B = 3.5644
Revenue TTM = 20.0m USD
EBIT TTM = -119.1m USD
EBITDA TTM = -118.1m USD
Long Term Debt = 8.19m USD (estimated: total debt 10.8m - short term 2.62m)
Short Term Debt = 2.62m USD (from shortTermDebt, last quarter)
Debt = 10.8m USD (from shortLongTermDebtTotal, last quarter) (leases 10.8m already included)
Net Debt = -466.0m USD (calculated: Debt 10.8m - CCE 476.8m)
Enterprise Value = 1.22b USD (1.68b + Debt 10.8m - CCE 476.8m)
Interest Coverage Ratio = unknown (Ebit TTM -119.1m / Interest Expense TTM 0.0)
EV/FCF = -15.11x (Enterprise Value 1.22b / FCF TTM -80.5m)
FCF Yield = -6.62% (FCF TTM -80.5m / Enterprise Value 1.22b)
FCF Margin = -402.7% (FCF TTM -80.5m / Revenue TTM 20.0m)
Net Margin = -536.4% (Net Income TTM -107.3m / Revenue TTM 20.0m)
Gross Margin = 94.92% ((Revenue TTM 20.0m - Cost of Revenue TTM 1.02m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.44 (Enterprise Value 1.22b / Total Assets 497.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 10.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -94.1m (EBIT -119.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.08 (Total Current Assets 484.7m / Total Current Liabilities 17.9m)
Debt / Equity = 0.02 (Debt 10.8m / totalStockholderEquity, last quarter 471.5m)
Debt / EBITDA = 3.94 (negative EBITDA) (Net Debt -466.0m / EBITDA -118.1m)
Debt / FCF = 5.79 (negative FCF - burning cash) (Net Debt -466.0m / FCF TTM -80.5m)
Total Stockholder Equity = 432.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.83% (Net Income -107.3m / Total Assets 497.6m)
RoE = -15.59% (Net Income TTM -107.3m / Total Stockholder Equity 687.9m)
RoCE = -17.12% (EBIT -119.1m / Capital Employed (Equity 687.9m + L.T.Debt 8.19m))
RoIC = -1.70k% (out of range, set to none) (NOPAT -94.1m / Invested Capital 5.53m)
WACC = 12.79% (E(1.68b)/V(1.69b) * Re(12.87%) + D(10.8m)/V(1.69b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.91 | Cagr: 53.24%
[DCF] Fair Price = unknown (Cash Flow -80.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.56 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-1.00 | Chg30d=-16.57% | Revisions=-20% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-1.00 | Chg30d=-5.08% | Revisions=-20% | Analysts=6
EPS current Year (2026-12-31): EPS=-3.47 | Chg30d=-3.15% | Revisions=+20% | GrowthEPS=-21.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.47 | Chg30d=-6.40% | Revisions=-20% | GrowthEPS=-28.7% | GrowthRev=-100.0%
[Analyst] Revisions Ratio: -20%